biotech

After the rapid strides it has made as a destination for biotech listings in less than three years, Hong Kong now faces bigger challenges in overtaking New York.

The Covid-19 pandemic is pushing renewed interest into healthcare sectors, where VC’s are looking for investments that not only survive but thrive under these unpredictable conditions.

Blackstone Life Sciences head Nicholas Galakatos talks regulation and the drug R&D process, and explains how investors can avoid mistakes in the pharmaceutical gold rush.

Can China Tower Corp revive investors’ interest after Xiaomi disappoints?

Wang Jun is an expert in genomics and life science. Here he tells FinanceAsia about his business plans for a digital life with iCarbonX – China's latest unicorn.

A shift from copycat drugs to a research-driven biotech industry is attracting expat scientists back home to help meet the challenges of an ageing population.

Biotech fever is beginning to stir in Hong Kong, but pioneer Dr Ming Pang believes Asia''s time has not come - yet.

e2-Capital wins three mandates to provide advisory and fundraising services to Chinese biotech projects.

As Hong Kong belatedly wakes up to the benefits of biotechnology, Singapore streaks ahead.